Literature DB >> 30592070

Serology-based criteria for adult coeliac disease have excellent accuracy across the range of pre-test probabilities.

Valma Fuchs1, Kalle Kurppa2, Heini Huhtala3, Kaija Laurila1, Markku Mäki2, Pekka Collin4, Teea Salmi1,5, Liisa Luostarinen6, Päivi Saavalainen7, Katri Kaukinen1,8.   

Abstract

BACKGROUND: The revised paediatric criteria for coeliac disease allow omission of duodenal biopsies in symptomatic children who have specific serology and coeliac disease-associated genetics. It remains unclear whether this approach is also applicable for adults with various clinical presentations. AIM: To evaluate the accuracy of serology-based criteria in adults with variable pre-test probabilities for coeliac disease.
METHODS: Three study cohorts comprised adults with high-risk clinical coeliac disease suspicion (n = 421), moderate-risk family members of coeliac disease patients (n = 2357), and low-risk subjects from the general population (n = 2722). Serological and clinical data were collected, and "triple criteria" for coeliac disease comprised transglutaminase 2 antibodies >10× the upper limit of normal, positive endomysium antibodies, and appropriate genetics without requirement of symptoms. The diagnosis was based on intestinal biopsy.
RESULTS: The diagnosis of coeliac disease was established in 274 subjects. Of these, 59 high-risk subjects, 17 moderate-risk subjects, and 14 low-risk subjects fulfilled the "triple criteria". All had histologically proven coeliac disease, giving the criteria a positive predictive value of 100%. Altogether, 90 (33%) of all 274 newly diagnosed patients could have avoided biopsy, including 37% among high-risk, 20% among moderate-risk, and 48% among low-risk patients. No histological findings other than coeliac disease were found in the biopsies of "triple positive" subjects.
CONCLUSIONS: Coeliac disease can reliably and safely be diagnosed without biopsy in adults fulfilling the "triple criteria" regardless of the pre-test probability. Revised criteria would enable the number of endoscopies to be reduced by one-third.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30592070     DOI: 10.1111/apt.15109

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Updated guidelines by the European Society for the Study of Coeliac Disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  United European Gastroenterol J       Date:  2019-06-01       Impact factor: 4.623

Review 2.  Celiac Disease Revisited.

Authors:  João Calado; Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2021-03-17

Review 3.  The global burden of coeliac disease: opportunities and challenges.

Authors:  Govind K Makharia; Prashant Singh; Carlo Catassi; David S Sanders; Daniel Leffler; Raja Affendi Raja Ali; Julio C Bai
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-03       Impact factor: 46.802

4.  Is duodenal biopsy always necessary for the diagnosis of coeliac disease in adult patients with high anti-tissue transglutaminase (TTG) antibody titres?

Authors:  Junaid Beig; Kamran Rostami; David T S Hayman; Summer Hassan; Stephen Gerred; Ravinder Ogra
Journal:  Frontline Gastroenterol       Date:  2021-06-25

Review 5.  Celiac Disease.

Authors:  Joshua Elliott Rubin; Sheila E Crowe
Journal:  Ann Intern Med       Date:  2020-01-07       Impact factor: 25.391

6.  Automatic classification of IgA endomysial antibody test for celiac disease: a new method deploying machine learning.

Authors:  Florentino Luciano Caetano Dos Santos; Irmina Maria Michalek; Kaija Laurila; Katri Kaukinen; Jari Hyttinen; Katri Lindfors
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

Review 7.  Celiac disease: a comprehensive current review.

Authors:  Giacomo Caio; Umberto Volta; Anna Sapone; Daniel A Leffler; Roberto De Giorgio; Carlo Catassi; Alessio Fasano
Journal:  BMC Med       Date:  2019-07-23       Impact factor: 8.775

8.  LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection.

Authors:  Juuso Rusanen; Anne Toivonen; Jussi Hepojoki; Satu Hepojoki; Pekka Arikoski; Markku Heikkinen; Outi Vaarala; Jorma Ilonen; Klaus Hedman
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

9.  Gluten and FODMAPS-Sense of a Restriction/When Is Restriction Necessary?

Authors:  Walburga Dieterich; Yurdagül Zopf
Journal:  Nutrients       Date:  2019-08-20       Impact factor: 5.717

10.  Non-Biopsy Serology-Based Diagnosis of Celiac Disease in Adults Is Accurate with Different Commercial Kits and Pre-Test Probabilities.

Authors:  Venla Ylönen; Katri Lindfors; Marleena Repo; Heini Huhtala; Valma Fuchs; Päivi Saavalainen; Alex Musikka; Kaija Laurila; Katri Kaukinen; Kalle Kurppa
Journal:  Nutrients       Date:  2020-09-08       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.